It’s almost impossible to value IMU with any degree of accuracy....

It’s almost impossible to value IMU with any degree of accuracy.

LC has told us “the whole B Cell platform is now validated”. IMU own the whole B Cell space. 100% .

From the results we have received so far B Cell outperforms T Cell therapy in efficacy. And furthermore it has been shown to have very little side effects or adverse events as opposed to T Cell therapy.

That would indicate that a minimum starting value would be higher than the sum of T Cell company valuations with an added premium for both safety and efficacy.

Last year sales of T Cell Immunotherapy drugs was US$169bn growing to $275bn in 2025.
If we work with a multiple of 5 times peak sales , the price paid by Big Pharma for acquisitions, we get a valuation range for T Cell Immunotherapy between US$875bn now and US$1375TN in 2025.

That’s not taking into account that 90% of Solid Tumour market that IMU can address via CF33/CD19 therapy. Again IMU is the only company in the world who can access this market.

My point isn’t to place a value on IMU, it’s about highlighting the size of the potential here. Taking a few minutes to explain why the ignorant journalist from the AFR needs to find a new career path.

We still have a way to go, but going on the outstanding performance of the @TeamImugene so far, I am very confident that shareholders are going to be very well rewarded.

This company will spin of many millionaires and more than a few billionaires.

I’ve still got every share I’ve bought over last 4 years. And looking to convert my options with cash.